Skip to main content
. 2024 Jun 24;14:1361420. doi: 10.3389/fonc.2024.1361420

Schema 1.

Schema 1

(A) Trial Design – Development of GFLIO ± DM ± Target Drugs. (B) Palliative Regimen. - Advanced Cholangiocarcinoma Palliative Regimen: All q2 weeks; -Parenthesis (): reference dosage reduction as needed for safety. - Bevacizumab replaces cetuximab at the time of progression. - Granulocyte Colony Stimulating Factor was added (300 mcg) on days 7 and 8 or 15 and 16 if the nadir neutrophil count is or will be <1000/µl or remains < 1250/µl, respectively.